Companies - Vivoryon Therapeutics

Price

 
Price
-
Change
-
Change %
-
Open
-
High
-
Low
-
Volume
-

Profile

 
Profile
Vivoryon Therapeutics AG (formerly Probiodrug AG), based in Halle, Germany, and its wholly-owned subsidiary Ingenium Pharmaceuticals GmbH (Munich, Germany) are active in research and development, as well as in preclinical and clinical studies. According to the stock market prospectus, for example, the glutaminyl cyclase enzyme, which according to the researchers plays a central role in the development of diseases, is the subject of research and a product to inhibit these enzymes is in the pipeline. The company was founded in 1997, was listed for the first time on the Euronext Amsterdam Stock Exchange at the end of 2014 and is listed on the OTC market in Germany.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2018)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-
Price to Earnings (3 years)
-
Price to Earnings (5 years)
-
Price to earnings growth
-
Price/cashflow
-
Price/net cashflow
-
Price/book value
-
Price to sales
-

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
-
Enterprise value/turnover
-38,667

Return ratios

Return on private equity
-
Return on total equity
-191,11%
Profit margin
-25.800,00%

Risk ratios

Solvability
-
Solvability
1,000
Current ratio
1,411
Debt to Equity
-

Value invest ratios

Grahams Number
€ -0,01
Grahams Value
€ -0,01
Grahams Product
-
Grahams Product (3 years)
-

2018

 

Profit and loss

Net profit (x 1 mln)
€ -7,74
Turnover (x 1 mln)
€ 0,03
Cashflow(x 1 mln)
€ -7,74
Net cashflow(x 1 mln)
€ -6,53

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
€ 4,05
Current assets (x 1 mln)
€ 3,98
Current liabilities (x 1 mln)
€ 2,82
Working capital (x 1 mln)
€ 1,16
Balance total (x 1 mln)
€ 4,05

Share

Outstanding shares (x 1 mln)
8,210
Price year-end
-
Dividend per share
-
Earnings per share
€ -0,94
Cashflow per share
€ -0,94
Net cashflow per share
€ -0,80
Book value per share
-
Stockmarket value (x 1 mln)
-

History

 
Year
2018
2017
2016
2015
2014
Net profit (x 1 mln)
€ -7,74
€ -8,01
€ -14,51
€ -13,40
€ -11,84
Turnover (x 1 mln)
€ 0,03
-
€ 0,09
€ 0,04
€ 0,06
Price year-end
-
€ 10,60
€ 18,03
€ 24,75
€ 19,15
Year high
-
€ 19,25
€ 27,73
€ 26,25
€ 25,00
Year low
-
€ 10,52
€ 15,00
€ 17,50
€ 15,50
Outstanding shares (x 1 mln)
8,210
8,210
8,187
6,872
4,862
Price to Earnings
-
-10,865
-10,170
-12,690
-7,864
Earnings per share
€ -0,94
€ -0,98
€ -1,77
€ -1,95
€ -2,44
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
-
-
€ 16,85
€ 16,13
€ 15,97
PE per share
-
-
€ 2,06
€ 2,35
€ 3,28
Balance total (x 1 mln)
€ 4,05
€ 10,76
€ 22,37
€ 21,87
€ 21,48
Stockmarket value (x 1 mln)
-
€ 87,03
€ 147,57
€ 170,05
€ 93,11

Company analysis

 

Analysis of profit indicators

Average profit per share (5 years)
€ -2,07
Standard deviation average profit
€ 0,74 (-35,91%)
Average annual growth rate
11,37%
Compound annual growth percentage
9,71%
© 2009 Skuzet. All Rights Reserved.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.